Targeting Deubiquitinating Enzyme USP26 by MicroRNA-203 Regulates Snail1's Pro-metastatic Functions in Esophageal Cancer
Overview
Affiliations
Background: Esophageal cancer is one of the most common cancers worldwide with poor prognosis and high mortality. The transcription factor , encoding Snail1, is important for metastatic progression in esophageal cancer whereas the microRNA (miRNA)-203 has been shown to function as an inhibitor of metastasis in EC. The Snail1 protein is stabilized in EC partially by the deubiquitinating enzyme USP26; however, how USP26 is regulated is not completely known.
Methods: Expression of and messenger RNA (mRNA) and miR-203 was performed in datasets within The Cancer Genome Atlas and Gene Expression Omnibus, respectively. Expression of Snail1 and USP26 protein and miR-203 was determined in the normal esophageal cell line HET-1A and EC cell lines Kyse150 and TE-1 using western blot and quantitative polymerase chain reaction, respectively. TargetScan was used for in situ prediction of miR-203 targets and in vitro heterologous reporter assays using the wild-type and miR-203 seed mutant of the 3' Untranslated region (UTR) of were used to investigate whether is a target of miR-203. Effects of increasing miR-203 using MIR203A/5P mimic on USP26 and Snail1 in the HET-1A, Kyse150 and TE-1 cell lines were performed using western blot and cycloheximide-based protein stability analysis. Effects of modulating miR-203 in Kyse150 and TE-1 cell lines on in vitro pro-metastatic effects were analyzed by invasion assay, scratch wound-healing assay, and chemosensitivity to 5-fluoruracil (5-FU). In vivo lung metastasis assay was used to study the effect of modulating miR-203 in Kyse150 cells.
Results: mRNA and was higher and lower, respectively, in EC patients compared to tumor-adjacent normal tissues. No changes in expression of mRNA were observed in these datasets. expression was downregulated whereas protein expression of both Snail1 and USP26 were higher in EC cell lines Kyse150 and TE-1 compared to normal esophageal cell line HET-1A. was predicted as a potential target of miR-203 by TargetScan Release 2.0. Reporter assays confirmed as a target of miR-203 in the EC cell lines. Transfection of EC cell lines with mimic decreased USP26 protein expression and Snail1 protein stability indicating the ability of miR-203 to regulate Snail1 protein levels via USP26. Exogenous increase in miR-203 in the EC cell lines significantly inhibited Snail-1 mediated in vitro pro-metastatic function of invasion, wound-healing, and increased chemosensitivity to 5-FU. Finally, overexpression of miR-203 inhibited in vivo lung metastasis of Kyse150 cells, which was reversed following overexpression of USP26, indicating a direct role of miR-203-mediated regulation of USP26 in metastatic progression of EC.
Conclusions: Cumulatively, these results establish an important mechanism by which decrease in miR-203 expression potentiates metastatic progression in EC via USP26-mediated stabilization of Snail1. Hence, miR-203 can serve as a biomarker of metastasis in EC and is a potential target for therapeutic intervention in EC.
Roles of deubiquitinases in urologic cancers (Review).
Wu L, Wang J, Chai L, Chen J, Jin X Oncol Lett. 2024; 28(6):609.
PMID: 39525605 PMC: 11544529. DOI: 10.3892/ol.2024.14743.
MicroRNAs: A novel signature in the metastasis of esophageal squamous cell carcinoma.
Wei Q, Jin F, Wang Z, Li B, Cao W, Sun Z World J Gastroenterol. 2024; 30(11):1497-1523.
PMID: 38617454 PMC: 11008420. DOI: 10.3748/wjg.v30.i11.1497.
Crosstalk Influences Proliferation, Migration, and Invasion in the Breast Cancer Cell.
Shi F, Chen X, Wang Y, Xie Y, Zhong J, Su K Int J Mol Sci. 2022; 23(19).
PMID: 36233075 PMC: 9569926. DOI: 10.3390/ijms231911755.
MicroRNAs and Corresponding Targets in Esophageal Cancer as Shown and in Preclinical Models.
Weidle U, Nopora A Cancer Genomics Proteomics. 2022; 19(2):113-129.
PMID: 35181582 PMC: 8865044. DOI: 10.21873/cgp.20308.
Marima R, Francies F, Hull R, Molefi T, Oyomno M, Khanyile R Biomedicines. 2021; 9(12).
PMID: 34944633 PMC: 8698559. DOI: 10.3390/biomedicines9121818.